MDXG Q2 2024 Earnings — MiMedx Group, Inc. Revenue & Financial Results | Market Cap Arena

MDXGMiMedx Group, Inc.

$684M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$87M+7.3% YoY

Gross Profit

$72M82.7% margin

Operating Income

$23M26.9% margin

Net Income

$18M20.2% margin

EPS (Diluted)

$0.12

QoQ Revenue Growth

+2.9%

Cash Flow

Operating Cash Flow

$22M

Free Cash Flow

$21M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$230M

Total Liabilities

$62M

Stockholders' Equity

$168M

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$87M	$81M	+7.3%
Gross Profit	$72M	$68M	+6.6%
Operating Income	$23M	$11M	+116.3%
Net Income	$18M	$1M	+1368.8%

Revenue Segments

Surgical

$30M100%